Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

• Disease Name: Ovarian High-Grade Serous Carcinoma
• MONDO ID: (if available)
• Category:

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Ovarian High-Grade Serous Carcinoma. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

• What are the primary pathophysiological mechanisms?
• What molecular pathways are dysregulated?
• What cellular processes are affected?

2. Key Molecular Players

• Genes/Proteins: Which genes are causally involved or implicated?
• Chemical Entities: What metabolites, drugs, or small molecules are relevant?
• Cell Types: Which cell types are primarily affected?
• Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

• What biological processes (GO terms) are disrupted?
• Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

• Where in the cell do key processes occur?
• Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

• What is the sequence of events from initial trigger to clinical manifestation?
• Are there distinct stages or phases?

6. Phenotypic Manifestations

• What are the key clinical phenotypes?
• How do they relate to the underlying mechanisms?

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic claims
• Prioritize recent reviews and landmark papers
• Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Comprehensive Research Report: Pathophysiology of Ovarian High‑Grade Serous Carcinoma (HGSC/HGSOC)

Target disease

• Disease name: Ovarian high-grade serous carcinoma (HGSC; often clinically grouped as “tubo‑ovarian” HGSC)
• Category: Epithelial ovarian cancer, Type II tumor (high genomic instability) (arcieri2024howbrcaand pages 1-2)
• MONDO ID: Not resolved in the current tool context. Closely related ontology entities captured in OpenTargets include ovarian serous adenocarcinoma (EFO_0002917) and ovarian serous carcinoma (EFO_1001516) (tool output referenced in context; not assigned a citeable context ID).

Key recent sources prioritized (2023–2024)

• Wang et al., Jan 2024, J Clin Invest (Review): https://doi.org/10.1172/jci174013 (wang2024biologydriventherapyadvances pages 1-2)
• Arcieri et al., Mar 2024, Frontiers in Oncology (Review): https://doi.org/10.3389/fonc.2024.1335196 (arcieri2024howbrcaand pages 1-2)
• Sveen et al., Jan 2024, JCI Insight (Primary, multisite WES): https://doi.org/10.1172/jci.insight.170423 (sveen2024evolutionarymodeand pages 1-2)
• Yoon et al., Aug 2024, Am J Surg Pathol (Primary, genomic catastrophe): https://doi.org/10.1097/PAS.0000000000002229 (yoon2024genomiccatastrophe(chromothripsis pages 1-3)
• Flesken‑Nikitin et al., Oct 2024, Nat Commun (Primary, cell-state origin): https://doi.org/10.1038/s41467-024-52984-1 (fleskennikitin2024preciliatedtubalepithelial pages 1-2)
• Talbot et al., Feb 2023, Cancer Gene Therapy (Review, copy-number targets): https://doi.org/10.1038/s41417-023-00589-z (talbot2023amplifiedtherapeutictargets pages 1-2)
• Micek et al., Feb 2023, APL Bioengineering (Primary, spheroid ECM): https://doi.org/10.1063/5.0132254 (micek2023modelofcollective pages 1-2)
• Sivakumar et al., Jan 2023, Clinical and Translational Medicine (Primary, spheroid dispersion): https://doi.org/10.1002/ctm2.1176 (sivakumar2023basalcelladhesion pages 1-3)
• Carey et al., Dec 2024, Journal of Ovarian Research (Primary, subtype–immune microenvironment): https://doi.org/10.1186/s13048-024-01556-4 (carey2024subtypespecificanalysisof pages 1-2)
• Balan et al., May 2024, Frontiers in Oncology (Review, single-cell/TME heterogeneity): https://doi.org/10.3389/fonc.2024.1388663 (balan2024unlockingovariancancer pages 1-2)

1) Key concepts and definitions (current understanding)

1.1 Definition and clinical identity

High-grade serous ovarian cancer (HGSOC/HGSC) is the dominant lethal epithelial ovarian cancer entity, accounting for ~70% of ovarian cancer cases and nearly ~80% of deaths (US 2023 projections embedded in review context) (wang2024biologydriventherapyadvances pages 1-2). It is frequently diagnosed at advanced stage and characterized by peritoneal dissemination (sveen2024evolutionarymodeand pages 1-2).

1.2 Cell of origin and precursor lesions: fallopian tube paradigm

The prevailing model is that many HGSCs originate in the distal fallopian tube (fimbria) from serous tubal intraepithelial carcinoma (STIC) precursors, rather than ovarian surface epithelium (OSE) (wang2024biologydriventherapyadvances pages 1-2).

Direct quote (definition-level): - “The concept that HGSOC originates in the secretory cells of the FTE is now at the forefront of the field.” (wang2024biologydriventherapyadvances pages 1-2)

A related evolutionary synthesis places distal fallopian tube origin at ~80% of cases (sveen2024evolutionarymodeand pages 1-2).

1.3 Hallmark genomic architecture: copy-number driven cancer

HGSC is a canonical chromosomal instability / copy-number alteration cancer with near-universal TP53 mutation and widespread gains/losses, rather than being dominated by recurrent point mutations (talbot2023amplifiedtherapeutictargets pages 1-2).

Direct quote: - “High-grade serous ovarian carcinoma is a unique cancer characterised by universal TP53 mutations and widespread copy number alterations.” (talbot2023amplifiedtherapeutictargets pages 1-2)

2) Core pathophysiology (molecular & cellular mechanisms)

2.1 Early initiating events: TP53 mutation and tubal epithelial transformation

A central near-universal early event is somatic TP53 mutation in tubal epithelium.

Direct quote: - “Somatic mutation of TP53 is thought to be the first mutagenic event in the fimbria…” (wang2024biologydriventherapyadvances pages 1-2)

Wang et al. also explicitly state TP53 alterations are “identified in more than 95% of cases of HGSOC” (wang2024biologydriventherapyadvances pages 1-2). TP53-mutant foci occur in histologically normal fimbrial epithelium (p53 signatures) and are associated with DNA damage markers (γ‑H2AX) (wang2024biologydriventherapyadvances pages 1-2).

2.2 DNA repair dysregulation: homologous recombination deficiency (HRD)

A major mechanistic axis is defective homologous recombination repair. - HRD affects ~50% of HGSC and drives genomic instability; this is the mechanistic basis of PARP inhibitor synthetic lethality (arcieri2024howbrcaand pages 1-2, sveen2024evolutionarymodeand pages 1-2).

Direct quote (review-level statement): - “About 50% of High Grade Serous Ovarian Cancer exhibit a high degree of genomic instability due to mutation of genes involved in Homologous Recombination (HRD)…” (arcieri2024howbrcaand pages 1-2)

2.3 Chromosomal instability (CIN), catastrophic genome events, and tumor geography

HGSC frequently exhibits structural genomic alterations, including catastrophic events.

Yoon et al. quantified catastrophic genomic events (CGE) (chromothripsis-like patterns and/or polyploidy): - CGE 15/26 (57.7%) - Chromothripsis-like patterns 13/26 (50.0%) - Polyploidy 6/26 (23.1%) (yoon2024genomiccatastrophe(chromothripsis pages 1-3)

These CGEs correlate with ovarian parenchymal involvement (9/9 with ovarian involvement vs 6/17 without; p=0.0024) (yoon2024genomiccatastrophe(chromothripsis pages 1-3), supporting biologically distinct growth/dissemination trajectories.

Yoon et al. further summarize phylogenetic timing models: ~6.5 years from STIC development to HGSC initiation, then metastasis over ~2 years (yoon2024genomiccatastrophe(chromothripsis pages 1-3).

2.4 Dissemination as an evolutionary process (multisite WES)

Sveen et al. reconstructed trajectories across 23 patients, sampling a median of 5 sites (total 108 samples) (sveen2024evolutionarymodeand pages 1-2). They describe: - Low median TMB: 1.1 nonsilent mutations/Mb (sveen2024evolutionarymodeand pages 1-2) - Three dissemination modes (monoclonal vs polyclonal; linear vs branched) (sveen2024evolutionarymodeand pages 1-2) - Disseminated clones often arise late, especially in DNA repair–deficient tumors (sveen2024evolutionarymodeand pages 1-2)

This aligns with an “early genomic destabilization, late dissemination burst” model that is clinically consistent with diagnosis at disseminated stage.

2.5 Metastatic units: spheroids in ascites and peritoneal implantation

HGSC frequently spreads transcoelomically via ascites, where tumor cells exist as single cells and multicellular spheroids (micek2023modelofcollective pages 1-2, sveen2024evolutionarymodeand pages 1-2).

Spheroid formation and ECM biology (2023 experimental model): Micek et al. developed an in vitro model distinguishing spheroids formed by single-cell aggregation vs collective detachment. Key data: - In vitro spheroids and ascites spheroids were similar in size (51 vs 55 μm, p>0.05) (micek2023modelofcollective pages 1-2). - Spheroids incorporate multiple ECM proteins; inhibiting RGD-based adhesion or fibronectin assembly reduced mesothelial adhesion strength under shear (micek2023modelofcollective pages 1-2).

Spheroid dispersion and mesothelial clearance (2023 mechanistic study): Sivakumar et al. identify BCAM (including soluble sBCAM shed by ADAM10) as a regulator of spheroid architecture and invasion.

Direct quote: - “…promotes the dispersion of OC cell spheroids by regulating LAMA5-integrin-β1-dependent compaction and thereby facilitating invasion of metastatic target sites.” (sivakumar2023basalcelladhesion pages 1-3)

2.6 Tumor microenvironment (TME) and immune ecosystems

Transcriptomic subtypes correspond to distinct microenvironmental states and clinical outcomes.

Carey et al. analyzed four mRNA subtypes (immunoreactive, differentiated, proliferative, mesenchymal) and immune infiltration: - Immunoreactive subtype: high immune infiltration including M1 (p<0.0001), M2 macrophages (p<0.01), Th1 cells (p<0.01) and extremely strong association with LAIR‑1 expression (p=1.63e‑101) (carey2024subtypespecificanalysisof pages 1-2). - Mesenchymal subtype: enriched for fibroblasts (p<0.0001) (carey2024subtypespecificanalysisof pages 1-2).

Balan et al. summarize the clinical backdrop for immune-directed strategies and highlight the role of immune evasion in limiting checkpoint blockade efficacy; they also note standard first-line response rates of ~80–90% yet frequent relapse with 5‑year survival ~35% in their overview (balan2024unlockingovariancancer pages 1-2).

3) Key molecular players (genes/proteins), chemicals, cell types, anatomy

Table: Overview of critical genes, pathways, and cellular processes identified as central to high-grade serous ovarian carcinoma pathophysiology in 2023–2025 literature.

3.1 Genes/proteins (HGNC)

Core annotated drivers and effectors include: - TP53, BRCA1, BRCA2, CCNE1, and frequent copy-number perturbations (e.g., PTEN, RB1, NF1 losses) (wang2024biologydriventherapyadvances pages 1-2, haagsma2025theroleof pages 20-24). - Metastasis/TME modules include BCAM–ADAM10–LAMA5–ITGB1 (spheroid dispersion, mesothelial clearance) (sivakumar2023basalcelladhesion pages 1-3). - Dissemination evolution includes recurrent alterations across sites in TP53, BRCA1/2, DNMT3A and PI3K/AKT pathway members (sveen2024evolutionarymodeand pages 1-2).

3.2 Chemical entities / drugs (CHEBI / pharmacologic)

Evidence-supported clinically deployed agents: - Platinum agents (carboplatin) + taxanes (paclitaxel) are standard first-line therapy (villatoro2025tumormicroenvironmentand pages 16-19). - PARP inhibitors: olaparib, rucaparib, niraparib (maintenance paradigms) (talbot2023amplifiedtherapeutictargets pages 1-2, arcieri2024howbrcaand pages 1-2). - Anti‑VEGF therapy (bevacizumab) in maintenance/combination contexts (villatoro2025tumormicroenvironmentand pages 16-19, wang2024biologydriventherapyadvances pages 1-2).

3.3 Key cell types (CL)

• Fallopian tube secretory epithelial lineage (origin), ciliated cells (protective/decline with age), tumor epithelial cells, mesothelial cells, macrophages (M1/M2), Th1 cells, B cells, fibroblasts/CAFs (wang2024biologydriventherapyadvances pages 1-2, fleskennikitin2024preciliatedtubalepithelial pages 1-2, carey2024subtypespecificanalysisof pages 1-2, sivakumar2023basalcelladhesion pages 1-3).

3.4 Anatomical locations (UBERON)

• Fallopian tube fimbria, ovary, peritoneum, omentum, and ascitic fluid/peritoneal fluid (sveen2024evolutionarymodeand pages 1-2, wang2024biologydriventherapyadvances pages 1-2, yoon2024genomiccatastrophe(chromothripsis pages 1-3, micek2023modelofcollective pages 1-2).

Table: A structured mapping of key genes, biological processes, cell types, and anatomical locations involved in High-Grade Serous Ovarian Carcinoma pathophysiology to standard ontology domains, supported by recent literature.

4) Biological processes disrupted (GO Biological Process targets)

Key disrupted processes for GO annotation (supported by the above sources): - DNA damage response / homologous recombination (HRD) (arcieri2024howbrcaand pages 1-2, sveen2024evolutionarymodeand pages 1-2) - Chromosome organization and chromosomal instability including chromothripsis/polyploidy (yoon2024genomiccatastrophe(chromothripsis pages 1-3) - Cell cycle regulation and replication stress (e.g., CCNE1-mediated G1/S dysregulation) (wang2024biologydriventherapyadvances pages 1-2, talbot2023amplifiedtherapeutictargets pages 1-2) - Cell adhesion and extracellular matrix remodeling in spheroids and peritoneal colonization (micek2023modelofcollective pages 1-2, sivakumar2023basalcelladhesion pages 1-3) - Angiogenesis / vascular permeability (VEGF-driven) (wang2024biologydriventherapyadvances pages 1-2) - Immune regulation and immune evasion with subtype-specific immune infiltration (carey2024subtypespecificanalysisof pages 1-2, balan2024unlockingovariancancer pages 1-2)

5) Cellular components (GO Cellular Component context)

Major cellular compartments implicated by mechanism: - Nucleus / chromatin (TP53, BRCA1/2, genomic instability) (wang2024biologydriventherapyadvances pages 1-2, arcieri2024howbrcaand pages 1-2) - DNA replication machinery / replication forks (replication stress; CCNE1) (wang2024biologydriventherapyadvances pages 1-2) - Plasma membrane (integrins, BCAM) and extracellular matrix (LAMA5, fibronectin/collagens in spheroids) (sivakumar2023basalcelladhesion pages 1-3, micek2023modelofcollective pages 1-2) - Tumor–stroma interface as a spatial functional unit in immune outcomes (subtype/TIME associations) (carey2024subtypespecificanalysisof pages 1-2)

6) Disease progression: sequence of events (initiation → clinical disease)

A consensus progression model supported by recent reviews and genomic studies: 1. Initiation in fimbrial fallopian tube epithelium: TP53 mutation and DNA damage accumulate; p53 signatures detectable (wang2024biologydriventherapyadvances pages 1-2). 2. Precursor lesions (STIC): share TP53 mutation; progress toward invasive carcinoma (wang2024biologydriventherapyadvances pages 1-2). 3. Genomic instability escalation: HRD in ~50% yields structural variation and copy-number complexity (arcieri2024howbrcaand pages 1-2, sveen2024evolutionarymodeand pages 1-2). 4. Dissemination via ascites: exfoliated tumor cells seed peritoneal cavity; diagnosis often stage III/IV (sveen2024evolutionarymodeand pages 1-2). 5. Spheroid-mediated peritoneal implantation: spheroids produce ECM and engage integrin-mediated adhesion; factors like BCAM modulate compaction and invasion (micek2023modelofcollective pages 1-2, sivakumar2023basalcelladhesion pages 1-3). 6. Metastatic colonization and ecosystem formation: omentum/peritoneum niches; subtype-specific immune ecosystems (carey2024subtypespecificanalysisof pages 1-2, sveen2024evolutionarymodeand pages 1-2).

Visual support: Wang et al. provide a schematic of this tubal origin and progression framework (wang2024biologydriventherapyadvances media 021dd764).

7) Phenotypic manifestations (clinical phenotypes linked to mechanisms)

7.1 Key clinical phenotypes

• Late-stage presentation with peritoneal dissemination: ~two-thirds stage III/IV at diagnosis (sveen2024evolutionarymodeand pages 1-2).
• High relapse frequency: recurrence in ~70% within 3 years after first-line chemotherapy (arcieri2024howbrcaand pages 1-2).
• Ascites and spheroids: ascites contributes to dissemination and therapy resistance; ascites present in a substantial fraction at diagnosis (nearly 40% of ovarian cancer patients at diagnosis in the provided synthesis) (haagsma2025theroleof pages 20-24).

7.2 Mechanistic linkage

• HRD → platinum/PARP sensitivity; HR-proficient/CCNE1-amplified → poorer chemotherapy response (wang2024biologydriventherapyadvances pages 1-2, arcieri2024howbrcaand pages 1-2).
• Mesenchymal subtype → stromal/ECM remodeling and poorer prognosis; immunoreactive subtype → higher immune infiltration and better prognosis (carey2024subtypespecificanalysisof pages 1-2).

8) Recent developments and latest research (2023–2024 emphasis)

8.1 Refining the cell-of-origin: lineage and cell-state susceptibility

Flesken‑Nikitin et al. (Nat Commun 2024) identify a transitional “pre‑ciliated” cell state in tubal epithelium as cancer-prone under Trp53/Rb1 pathway perturbations, suggesting initiation susceptibility may not be limited to mature secretory cells (fleskennikitin2024preciliatedtubalepithelial pages 1-2).

8.2 Genome evolution and dissemination timing at multisite resolution

Sveen et al. (JCI Insight 2024) quantify low TMB, high CNA burden, and multiple dissemination modes; chemotherapy exposure is associated with higher genomic diversity in disseminated clones (sveen2024evolutionarymodeand pages 1-2).

8.3 Catastrophic genomic events and tumor distribution

Yoon et al. (Am J Surg Pathol 2024) provide strong quantitative evidence that CGE (chromothripsis/polyploidy) is common and correlates with ovarian parenchymal involvement, supporting heterogeneous evolutionary trajectories and possibly multiple “routes” to extensive disease (yoon2024genomiccatastrophe(chromothripsis pages 1-3).

8.4 Functional metastasis mechanisms in spheroids

2023 mechanistic studies emphasize spheroids as metastasis units, including ECM production post-detachment and BCAM-dependent modulation of compaction and invasion (micek2023modelofcollective pages 1-2, sivakumar2023basalcelladhesion pages 1-3).

8.5 Immune microenvironment stratification

Carey et al. (2024) provide subtype-specific immune associations with extremely strong p-values (e.g., LAIR‑1 p=1.63e‑101), illustrating that subtype classification may be operationalized for immune stratification (carey2024subtypespecificanalysisof pages 1-2).

9) Current applications and real-world implementations

9.1 Molecular testing in practice

European and American guidelines recommend BRCA testing for all new high‑grade ovarian cancer diagnoses, and HRD testing to guide PARP inhibitor use (arcieri2024howbrcaand pages 1-2).

9.2 Targeted therapies and biomarker-linked benefit

• PARP inhibitor maintenance benefits (trial summary values as reported in 2023 review):
• Olaparib: PFS improvement 13.6 months in BRCA1/2-mut maintenance setting; OS difference 12.9 months in final unadjusted analysis (not statistically significant) (talbot2023amplifiedtherapeutictargets pages 1-2).
• Rucaparib: PFS benefit 9.2 months in BRCA-mut and 5.4 months in ITT (talbot2023amplifiedtherapeutictargets pages 1-2).
• Niraparib: PFS benefit 11.5 months (first-line HRD group) and 5.6 months overall (talbot2023amplifiedtherapeutictargets pages 1-2).
• VEGF-driven angiogenesis is a therapeutic dependency; bevacizumab improves PFS in maintenance in standard-of-care frameworks (villatoro2025tumormicroenvironmentand pages 16-19, wang2024biologydriventherapyadvances pages 1-2).

9.3 Translational directions

• Targeting spheroid adhesion/ECM interactions (integrin, fibronectin assembly) and regulators of spheroid architecture (BCAM/ADAM10 axis) represent testable metastasis-focused strategies (micek2023modelofcollective pages 1-2, sivakumar2023basalcelladhesion pages 1-3).

10) Evidence items (knowledge base–oriented)

10.1 Mechanistic evidence highlights (with direct quotes)

• TP53 universality and early event: “Somatic mutation of TP53 is thought to be the first mutagenic event in the fimbria…” (wang2024biologydriventherapyadvances pages 1-2).
• TP53 frequency: TP53 alterations are “identified in more than 95% of cases of HGSOC” (wang2024biologydriventherapyadvances pages 1-2).
• Copy-number driven cancer definition: “High-grade serous ovarian carcinoma is a unique cancer characterised by universal TP53 mutations and widespread copy number alterations.” (talbot2023amplifiedtherapeutictargets pages 1-2).
• Spheroid invasion mechanism: “…promotes the dispersion of OC cell spheroids by regulating LAMA5-integrin-β1-dependent compaction…” (sivakumar2023basalcelladhesion pages 1-3).

10.2 Quantitative/statistical anchors

• US 2023 burden (review-cited): 19,710 new diagnoses and 13,270 deaths projected in 2023 (wang2024biologydriventherapyadvances pages 1-2).
• Global burden: >150,000 OC-related deaths annually worldwide (wang2024biologydriventherapyadvances pages 1-2).
• HRD frequency: ~50% (arcieri2024howbrcaand pages 1-2, sveen2024evolutionarymodeand pages 1-2).
• Dissemination: ~two-thirds stage III/IV at diagnosis (sveen2024evolutionarymodeand pages 1-2).
• Catastrophic genomic events: 57.7% overall; chromothripsis-like 50%; polyploidy 23.1% (yoon2024genomiccatastrophe(chromothripsis pages 1-3).
• Multisite WES: median TMB 1.1 nonsilent/Mb (sveen2024evolutionarymodeand pages 1-2).

10.3 Limitations of this extraction

• PMIDs were not explicitly present in the retrieved text excerpts; therefore, citations are provided via DOIs and journal metadata. Where PubMed IDs exist in the broader literature, they were not exposed in the present tool-retrieved text segments.
• Some ontology IDs are provided as examples; where IDs were not resolvable from the current context, this is explicitly indicated in artifact-01.

Figure evidence

A schematic figure depicting the tubal origin model and progression from TP53-mutant FTE/p53 signature → STIC → carcinoma/metastasis was extracted from Wang et al. (JCI 2024) (wang2024biologydriventherapyadvances media 021dd764).

References

1. (arcieri2024howbrcaand pages 1-2): Martina Arcieri, Veronica Tius, Claudia Andreetta, Stefano Restaino, Anna Biasioli, Elena Poletto, Giuseppe Damante, Alfredo Ercoli, Lorenza Driul, Anna Fagotti, Domenica Lorusso, Giovanni Scambia, and Giuseppe Vizzielli. How brca and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature. Frontiers in Oncology, Mar 2024. URL: https://doi.org/10.3389/fonc.2024.1335196, doi:10.3389/fonc.2024.1335196. This article has 36 citations.

2. (wang2024biologydriventherapyadvances pages 1-2): Yinu Wang, Alexander James Duval, Mazhar Adli, and Daniela Matei. Biology-driven therapy advances in high-grade serous ovarian cancer. The Journal of Clinical Investigation, Jan 2024. URL: https://doi.org/10.1172/jci174013, doi:10.1172/jci174013. This article has 69 citations.

3. (sveen2024evolutionarymodeand pages 1-2): Anita Sveen, Bjarne Johannessen, Solveig M.K. Klokkerud, Sigrid M. Kraggerud, Leonardo A. Meza-Zepeda, Merete Bjørnslett, Katharina Bischof, Ola Myklebost, Kjetil Taskén, Rolf I. Skotheim, Anne Dørum, Ben Davidson, and Ragnhild A. Lothe. Evolutionary mode and timing of dissemination of high-grade serous carcinomas. JCI Insight, Jan 2024. URL: https://doi.org/10.1172/jci.insight.170423, doi:10.1172/jci.insight.170423. This article has 5 citations and is from a domain leading peer-reviewed journal.

4. (yoon2024genomiccatastrophe(chromothripsis pages 1-3): Ju-Yoon Yoon, Aarti Sharma, Azra H. Ligon, Rebecca G. Ramesh, T. Rinda Soong, Wa Xian, David B. Chapel, and Christopher P. Crum. Genomic catastrophe (chromothripsis and polyploidy) correlates with tumor distribution in extrauterine high-grade serous carcinoma. The American Journal of Surgical Pathology, 48:1017-1023, Apr 2024. URL: https://doi.org/10.1097/pas.0000000000002229, doi:10.1097/pas.0000000000002229. This article has 0 citations.

5. (fleskennikitin2024preciliatedtubalepithelial pages 1-2): Andrea Flesken-Nikitin, Coulter Q. Ralston, Dah-Jiun Fu, Andrea J. De Micheli, Daryl J. Phuong, Blaine A. Harlan, Amanda P. Armstrong, David McKellar, Sangeeta Ghuwalewala, John C. Schimenti, Benjamin D. Cosgrove, and Alexander Yu. Nikitin. Pre-ciliated tubal epithelial cells are prone to initiation of high-grade serous ovarian carcinoma. Nature Communications, Dec 2024. URL: https://doi.org/10.1038/s41467-024-52984-1, doi:10.1038/s41467-024-52984-1. This article has 21 citations and is from a highest quality peer-reviewed journal.

6. (talbot2023amplifiedtherapeutictargets pages 1-2): Thomas Talbot, Haonan Lu, and Eric O. Aboagye. Amplified therapeutic targets in high-grade serous ovarian carcinoma – a review of the literature with quantitative appraisal. Cancer Gene Therapy, 30:955-963, Feb 2023. URL: https://doi.org/10.1038/s41417-023-00589-z, doi:10.1038/s41417-023-00589-z. This article has 8 citations and is from a peer-reviewed journal.

7. (micek2023modelofcollective pages 1-2): Hannah M. Micek, Lauren Rosenstock, Yicheng Ma, Caitlin Hielsberg, Lauren Montemorano, Metti K. Gari, Suzanne M. Ponik, and Pamela K. Kreeger. Model of collective detachment in high-grade serous ovarian cancer demonstrates that tumor spheroids produce ecm to support metastatic processes. APL Bioengineering, Feb 2023. URL: https://doi.org/10.1063/5.0132254, doi:10.1063/5.0132254. This article has 4 citations.

8. (sivakumar2023basalcelladhesion pages 1-3): Suresh Sivakumar, Sonja Lieber, Damiano Librizzi, Corinna Keber, Leah Sommerfeld, Florian Finkernagel, Katrin Roth, Silke Reinartz, Jörg W. Bartsch, Johannes Graumann, Sabine Müller‐Brüsselbach, and Rolf Müller. Basal cell adhesion molecule promotes metastasis‐associated processes in ovarian cancer. Clinical and Translational Medicine, Jan 2023. URL: https://doi.org/10.1002/ctm2.1176, doi:10.1002/ctm2.1176. This article has 7 citations and is from a peer-reviewed journal.

9. (carey2024subtypespecificanalysisof pages 1-2): Kaylin M. Carey, Corey D. Young, Alexis J. Clark, Eric B. Dammer, Rajesh Singh, and James W. Lillard. Subtype-specific analysis of gene co-expression networks and immune cell profiling reveals high grade serous ovarian cancer subtype linkage to variable immune microenvironment. Journal of Ovarian Research, Dec 2024. URL: https://doi.org/10.1186/s13048-024-01556-4, doi:10.1186/s13048-024-01556-4. This article has 5 citations and is from a peer-reviewed journal.

10. (balan2024unlockingovariancancer pages 1-2): Dharvind Balan, Nirmala Chandralega Kampan, Magdalena Plebanski, and Nor Haslinda Abd Aziz. Unlocking ovarian cancer heterogeneity: advancing immunotherapy through single-cell transcriptomics. Frontiers in Oncology, May 2024. URL: https://doi.org/10.3389/fonc.2024.1388663, doi:10.3389/fonc.2024.1388663. This article has 15 citations.

11. (haagsma2025theroleof pages 20-24): J Haagsma. The role of tp53 mutation in reducing inflammatory signaling and promoting precursor cell spheroid survival in ovarian high-grade serous carcinoma. Unknown journal, 2025.

12. (villatoro2025tumormicroenvironmentand pages 16-19): FP Villatoro. Tumor microenvironment and genomic biomarkers for precision oncology in high-grade serous ovarian cancer. Unknown journal, 2025.

13. (micoli2025decodingthegenomic pages 1-2): Giulia Micoli, Kari Lavikka, Yilin Li, Anna Pirttikoski, Daria Afenteva, Wojciech Senkowski, Giovanni Marchi, Anna Vaharautio, Taru A. Muranen, Titta Joutsiniemi, Sakari Hietanen, Anni Virtanen, Krister Wennerberg, Johanna Hynninen, Jaana Oikkonen, and Sampsa Hautaniemi. Decoding the genomic and functional landscape of emerging subtypes in ovarian cancer. Cancer discovery, Jul 2025. URL: https://doi.org/10.1158/2159-8290.cd-25-0652, doi:10.1158/2159-8290.cd-25-0652. This article has 2 citations and is from a highest quality peer-reviewed journal.

14. (haagsma2025theroleof pages 24-27): J Haagsma. The role of tp53 mutation in reducing inflammatory signaling and promoting precursor cell spheroid survival in ovarian high-grade serous carcinoma. Unknown journal, 2025.

15. (wang2024biologydriventherapyadvances media 021dd764): Yinu Wang, Alexander James Duval, Mazhar Adli, and Daniela Matei. Biology-driven therapy advances in high-grade serous ovarian cancer. The Journal of Clinical Investigation, Jan 2024. URL: https://doi.org/10.1172/jci174013, doi:10.1172/jci174013. This article has 69 citations.